Silk-Based Protein Corona Enhances mRNA-LNP Vaccine Efficacy and Prevents Tumor Relapse.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42249645.
- Also identified by DOI 10.1002/adma.202521487.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lipid nanoparticles (LNPs) are clinically validated carriers for nucleic acid therapeutics; however, achieving targeted delivery to reticuloendothelial organs beyond the liver, lung, and spleen remains a major challenge. Here, we introduce a strategy for post-fabrication engineering of a custom protein corona on mRNA-LNPs using cationic silk fibroin (SF), a biocompatible and chemically tunable protein polymer. SF-coated LNPs exhibit enhanced cellular uptake and endosomal escape, resulting in a 3.6 fold increase in lymph node delivery and a 2.5 fold extension in in vivo protein expression compared to unmodified LNPs. In a cancer vaccine model, SF-LNPs significantly improve dendritic cell maturation, antigen cross-presentation, and cytotoxic T cell activation, leading to robust protection against tumor growth and metastasis, as well as durable immunological memory. This work expands the formulation space for LNPs and establishes silk fibroin as a modular surface engineering tool for enhancing the efficacy and specificity of mRNA-based therapeutics.